DR-0201 (SAR448501) is a bispecific monoclonal antibody that binds CD20 on the surface of B cells. It blocks CD20-mediated signaling and can trigger phagocytosis of CD20-expressing cells by macrophages, depleting pathogenic B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
SAR448501
Drug type
Bispecific antibody
Targets
CD20 (MS4A1)
Mechanism
Modulator of CD20 (MS4A1)
Pathways
CD20-mediated signaling blockade, macrophage-mediated phagocytosis of CD20-overexpressing cells, B-cell depletion
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.